Clinical Trial Update: Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating monthly and twice-monthly subcutaneous dosing of PF-04950615 (RN316) in hypercholesterolemia patients on statins. The study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• PF-04950615 (RN316) (PF-04950615)

Snippet

Sponsor: Pfizer | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2017-12-05